Skip to main content
. 2013 Oct 18;288(48):34930–34942. doi: 10.1074/jbc.M113.513333

FIGURE 2.

FIGURE 2.

EGFR-GFP Mut R1-6/L393H is retained and intact within the ER. A, attached RBL mast cells transiently expressing WT EGFR-GFP, EGFR-GFP Mut R1-6, EGFR-GFP L393H, or EGFR-GFP Mut R1-6/L393H were fixed, permeabilized, and labeled with an anti-PDI antibody followed by Alexa555-anti-mouse IgG to label the ER. Scale bar, 10 μm. B, whole cell lysates from RBL mast cells transiently expressing either WT EGFR, EGFR Mut R1-6, or EGFR Mut R1-6/L393H (LH) were untreated (Un), treated with Endo H (EH), or treated with PNGase F (PNG) for 24 h before Western blot analysis with an anti-EGFR antibody.